Ausiello Dennis A 4

What Happened
Dennis A. Ausiello, a director of Seres Therapeutics (MCRB), was granted a derivative award covering 7,508 shares on July 1, 2026. The acquisition is reported as $0.00 (derivative), indicating an option/award rather than an open-market purchase or sale. This is an award/grant (transaction code A), not a sale.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (timely, next-day filing).
• Reported amount: 7,508 shares; acquisition price shown as $0.00 (derivative award).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnote: the option vests in four equal quarterly installments on Oct 1, 2026; Jan 1, Apr 1, and Jul 1, 2027. If the company's 2027 annual meeting occurs before July 1, 2027, the final installment vests immediately prior to that meeting. Vesting is conditioned on Ausiello remaining a non-employee director through each vesting date.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag noted in the excerpt.

Context
This was a derivative grant (an option/award) rather than a cash purchase or sale. Such grants are typically compensation-related and vest over time; they do not indicate an immediate purchase of stock unless and until the options are exercised and shares are acquired. The filing does not disclose the option exercise price or other economic terms beyond the vesting schedule in the footnote.